Oncotelic Therapeutics, Inc. (OTCQB: OTLC) will take center stage at the 22nd Drug Discovery Strategic Summit, where Chief Business Officer Saran Saund is set to deliver the opening keynote on the second day, Oct. 22, 2026, at 9 a.m. Pacific Time in Millbrae, California. The presentation will focus on partition and aggregation as an organizing principle for AI-enabled drug discovery, a framework that breaks complex research questions into focused investigations and then combines findings to develop testable hypotheses. For investors and industry observers, the keynote offers a window into how Oncotelic is positioning its proprietary PDAOAI platform, which indexes approximately 29 million PubMed abstracts, as a scalable tool for accelerating early-stage research.
The significance extends beyond a single conference appearance. Oncotelic is also outlining an international intellectual property strategy and planned expansion into genetic discovery, alongside Fastbot/Membot technology designed to make AI-powered research accessible to individual investigators. If successful, that approach could lower barriers for smaller research teams and independent scientists, potentially democratizing a field increasingly dominated by large, well-funded players. The full press release is available at https://nnw.fm/O1lLk, and ongoing updates on the company can be found in its newsroom at https://nnw.fm/OTLC.
Oncotelic develops oncology and immunotherapy products, with a focus on cancers with substantial unmet needs and rare pediatric indications, and it also develops the PDAOAI platform to support its drug discovery and development work. The company’s dual focus on therapeutics and AI infrastructure means the summit keynote could resonate across both biotech and technology investors. The announcement was distributed through NetworkNewsWire, a specialized communications platform focused on financial news and content distribution for private and public companies and the investment community. NNW is one of 75+ brands within the Dynamic Brand Portfolio at IBN, which provides access to wire solutions through InvestorWire and other services.
The broader implication is that AI-enabled drug discovery is moving from proof-of-concept toward operational platforms that can be evaluated by the investment community. Oncotelic’s emphasis on indexing tens of millions of abstracts and on tools for individual investigators suggests a bet that speed and accessibility will matter as much as raw compute power. For readers tracking biotech innovation, the Oct. 22 keynote will be an early test of whether that thesis gains traction among researchers and potential partners. Terms of use and disclaimers for the distributed content are available at https://www.NetworkNewsWire.com/Disclaimer.
